Avalyn Pharma Q2 2026 Earnings Results & Report

Avalyn Pharma EPS Results

• Actual EPS: -$0.98
• Consensus EPS: -$1.03
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: N/A

Avalyn Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Avalyn Pharma (NASDAQ:AVLN), Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review. Avalyn is headquartered in the United States and conducts its work in collaboration with clinical, research and development partners. Information about additional commercial operations and geographic markets is limited because the company remains focused on clinical development rather than marketed products.